AI Article Synopsis

  • * Research has shown that whole-body irradiation (excluding the head) can reduce SLE-like symptoms in NZBWF1 mice by preventing kidney damage and lowering harmful antibody levels.
  • * The study indicates that irradiation decreases CD180-negative cells in the spleen, suggesting that targeting these cells might offer a new therapeutic strategy for managing SLE symptoms, despite challenges in clinical trials.

Article Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies that can induce systemic inflammation. Ultraviolet-A and X-ray irradiation have been reported to have therapeutic effects in patients with SLE. We previously demonstrated that CD180-negative cells, these are radiosensitive, contribute to the development of SLE-like morbidity in NZBWF1 mice. In this study, the effects of irradiation on SLE-like morbidity manifestations in NZBWF1 mice and on CD180-negative cells were investigated. Whole-body irradiation, excluding the head, attenuated SLE-like morbidity , as indicated by the prevention of the renal lesion development, inhibition of anti-dsDNA antibody production, reduction of urinary protein levels, and prolongation of the lifespan. Irradiation also reduced the proportion of CD180-negative cells in the spleen. Although other immune cells or molecules may be triggered because of the whole-body irradiation treatment, previous research, and the current results suggest a strong relationship between the radiation-induced decrease in CD180-negative cells and the amelioration of SLE-like morbidities. Clinical trials assessing CD180-negative cells as a therapeutic target for SLE have been hampered by the lack of validated cell markers; nonetheless, the present findings suggest that radiotherapy may be a new therapeutic strategy for managing SLE symptoms.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599955PMC
http://dx.doi.org/10.1155/2023/9969079DOI Listing

Publication Analysis

Top Keywords

cd180-negative cells
24
nzbwf1 mice
12
sle-like morbidity
12
systemic lupus
8
morbidity nzbwf1
8
whole-body irradiation
8
cells
7
irradiation
6
cd180-negative
6
irradiation attenuates
4

Similar Publications

CD180 is a toll-like receptor that is highly expressed in complex with the MD-1 satellite molecule on the surface of B cells. In chronic lymphocytic leukaemia (CLL) however, the expression of CD180 is highly variable and overall, significantly reduced when compared to normal B cells. We have recently shown that reduced CD180 expression in CLL lymph nodes is associated with inferior overall survival.

View Article and Find Full Text PDF
Article Synopsis
  • * Research has shown that whole-body irradiation (excluding the head) can reduce SLE-like symptoms in NZBWF1 mice by preventing kidney damage and lowering harmful antibody levels.
  • * The study indicates that irradiation decreases CD180-negative cells in the spleen, suggesting that targeting these cells might offer a new therapeutic strategy for managing SLE symptoms, despite challenges in clinical trials.
View Article and Find Full Text PDF

Activation of TLR7 and TLR9 by endogenous RNA- or DNA-containing ligands, respectively, can lead to hyper-activation of immune cells, including macrophages and DCs, subsequently contributes to the pathogenesis of SLE. CD180, a TLR-like protein, is specifically involved in the development and activation of immune cells. Our previous study and others have reported that CD180-negative B cells are dramatically increased in SLE patients and responsible for the production of auto-antibodies.

View Article and Find Full Text PDF

Discordant frequencies of tissue-resident and circulating CD180-negative B cells in chronic rhinosinusitis.

Int Forum Allergy Rhinol

June 2017

Department of Surgery-Otolaryngology Head and Neck Surgery, University of Adelaide, Adelaide, South Australia, Australia.

Background: The unconventional toll-like receptor (TLR) CD180 is implicated in chronic inflammatory diseases; however, its role in chronic rhinosinusitis (CRS) has yet to be investigated. Here we study the expression of CD180, its homologue TLR4 and myeloid differentiation factor 1 (MD1) on mucosal and systemic immune cell populations in relation to serum immunoglobulin G (IgG) levels.

Methods: A total of 70 patients were recruited to the study.

View Article and Find Full Text PDF

Ligation of CD180 inhibits IFN-α signaling in a Lyn-PI3K-BTK-dependent manner in B cells.

Cell Mol Immunol

February 2017

The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing 210093, People's Republic of China.

A hallmark of systemic lupus erythematosus (SLE) is the consistent production of various auto-antibodies by auto-reactive B cells. Interferon-α (IFN-α) signaling is highly activated in SLE B cells and plays a vital role in the antibody response by B cells. Previous studies have shown that CD180-negative B cells, which are dramatically increased in SLE patients, are responsible for the production of auto-antibodies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!